Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 1
2014 2
2015 4
2016 7
2017 6
2018 14
2019 13
2020 13
2021 25
2022 17
2023 16

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs.
Xu H, Zhang J, Zheng X, Tan P, Xiong X, Yi X, Yang Y, Wang Y, Liao D, Li H, Wei Q, Ai J, Yang L. Xu H, et al. Cell Death Dis. 2022 Nov 10;13(11):949. doi: 10.1038/s41419-022-05392-6. Cell Death Dis. 2022. PMID: 36357378 Free PMC article.
All of these genes were upregulated in PCa tissues, associated with worse clinicopathological outcomes and downregulated after SR9009 treatment. Nevertheless, knockdown or knockout of REV-ERB could not rescue the anticancer effect of SR9009 in PCa. Further analysis …
All of these genes were upregulated in PCa tissues, associated with worse clinicopathological outcomes and downregulated after SR9009 …
SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy.
Shen W, Zhang W, Ye W, Wang H, Zhang Q, Shen J, Hong Q, Li X, Wen G, Wei T, Zhang J. Shen W, et al. Theranostics. 2020 Mar 15;10(10):4466-4480. doi: 10.7150/thno.42478. eCollection 2020. Theranostics. 2020. PMID: 32292508 Free PMC article.
Autophagy regulation by REV-ERBalpha and its possible mechanism in SR9009-based SCLC therapy were analyzed. Results: Here, we showed that the REV-ERB agonist SR9009 is specifically lethal to both chemosensitive and chemoresistant SCLC cells. REV-ERBalpha was involve …
Autophagy regulation by REV-ERBalpha and its possible mechanism in SR9009-based SCLC therapy were analyzed. Results: Here, we showed …
SR9009 improves heart function after pressure overload independent of cardiac REV-ERB.
Li H, Song S, Tien CL, Qi L, Graves A, Nasiotis E, Burris TP, Zhao Y, Sun Z, Zhang L. Li H, et al. Front Cardiovasc Med. 2022 Jul 14;9:952114. doi: 10.3389/fcvm.2022.952114. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35911512 Free PMC article.
However, it is unknown whether SR9009 indeed works through cardiac REV-ERB, given that SR9009 might target other proteins and that REV-ERB in non-cardiac tissues might regulate cardiac functions indirectly. ...We found that REV-ERB cardiac deficiency leads to profou …
However, it is unknown whether SR9009 indeed works through cardiac REV-ERB, given that SR9009 might target other proteins and …
SR9009 Regulates Acute Lung Injury in Mice Induced by Sepsis.
Hu M, Zhang L, Cao J, Jiang Y, Liu G. Hu M, et al. Can Respir J. 2022 Jul 1;2022:5802938. doi: 10.1155/2022/5802938. eCollection 2022. Can Respir J. 2022. PMID: 35814267 Free PMC article.
The inflammatory response is obviously enhanced in LPS-constructed sepsis mice and alleviated by SR9009 agonist treatment. Cell-based experiments reveal that pharmacological activation of Rev-Erbalpha via SR9009 attenuates the LPS-induced inflammatory response by su …
The inflammatory response is obviously enhanced in LPS-constructed sepsis mice and alleviated by SR9009 agonist treatment. Cell-based …
REV-ERBα Agonist SR9009 Promotes a Negative Energy Balance in Goldfish.
Saiz N, Herrera-Castillo L, Isorna E, Delgado MJ, Conde-Sieira M, Soengas JL, de Pedro N. Saiz N, et al. Int J Mol Sci. 2022 Mar 8;23(6):2921. doi: 10.3390/ijms23062921. Int J Mol Sci. 2022. PMID: 35328345 Free PMC article.
Moreover, SR9009 decreased plasma glucose, coinciding with increased glycolysis and a decreased gluconeogenesis in the liver. Decreased triglyceride levels and activity of lipogenic enzymes suggest a lipogenesis reduction by SR9009. Energy expenditure by locomotor a …
Moreover, SR9009 decreased plasma glucose, coinciding with increased glycolysis and a decreased gluconeogenesis in the liver. Decreas …
Rev-erbs agonist SR9009 alleviates ischemia-reperfusion injury by heightening endogenous cardioprotection at onset of type-2 diabetes in rats: Down-regulating ferritinophagy/ferroptosis signaling.
Huang Q, Tian L, Zhao X, Lei S, Zhao B, Qiu Z, Xia ZY. Huang Q, et al. Biomed Pharmacother. 2022 Oct;154:113595. doi: 10.1016/j.biopha.2022.113595. Epub 2022 Aug 24. Biomed Pharmacother. 2022. PMID: 36029539 Free article.
Targeting Rev-erbs might limit ferroptosis, with increasing attention turning to the application of circadian medicine against IR injuries. However, whether the Rev-erbs agonist SR9009 could mitigate diabetic IR injury remains unknown. Here, we investigated the susceptibil …
Targeting Rev-erbs might limit ferroptosis, with increasing attention turning to the application of circadian medicine against IR injuries. …
SR9009 has REV-ERB-independent effects on cell proliferation and metabolism.
Dierickx P, Emmett MJ, Jiang C, Uehara K, Liu M, Adlanmerini M, Lazar MA. Dierickx P, et al. Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12147-12152. doi: 10.1073/pnas.1904226116. Epub 2019 May 24. Proc Natl Acad Sci U S A. 2019. PMID: 31127047 Free PMC article.
However, the direct involvement of REV-ERBs in these effects of SR9009 has not been thoroughly assessed, as experiments were not performed in the complete absence of both proteins. ...Thus, the effects of SR9009 cannot be used solely as surrogate for REV-ERB activit …
However, the direct involvement of REV-ERBs in these effects of SR9009 has not been thoroughly assessed, as experiments were not perf …
REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis.
Wang S, Lin Y, Yuan X, Li F, Guo L, Wu B. Wang S, et al. Nat Commun. 2018 Oct 12;9(1):4246. doi: 10.1038/s41467-018-06568-5. Nat Commun. 2018. PMID: 30315268 Free PMC article.
Interestingly, Rev-erbalpha activation in wild-type mice by SR9009 attenuates DSS-induced colitis, whereas the protective effects are lost in Nlrp3(-/-) and Rev-erbalpha(-/-) mice. ...
Interestingly, Rev-erbalpha activation in wild-type mice by SR9009 attenuates DSS-induced colitis, whereas the protective effects are …
Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence.
Sulli G, Rommel A, Wang X, Kolar MJ, Puca F, Saghatelian A, Plikus MV, Verma IM, Panda S. Sulli G, et al. Nature. 2018 Jan 18;553(7688):351-355. doi: 10.1038/nature25170. Epub 2018 Jan 10. Nature. 2018. PMID: 29320480 Free PMC article.
The anticancer activity of SR9009 and SR9011 affects a number of oncogenic drivers (such as HRAS, BRAF, PIK3CA and others) and persists in the absence of p53 and under hypoxic conditions. The regulation of autophagy and de novo lipogenesis by SR9009 and SR9011 has a …
The anticancer activity of SR9009 and SR9011 affects a number of oncogenic drivers (such as HRAS, BRAF, PIK3CA and others) and persis …
Deficiency of intestinal Bmal1 prevents obesity induced by high-fat feeding.
Yu F, Wang Z, Zhang T, Chen X, Xu H, Wang F, Guo L, Chen M, Liu K, Wu B. Yu F, et al. Nat Commun. 2021 Sep 7;12(1):5323. doi: 10.1038/s41467-021-25674-5. Nat Commun. 2021. PMID: 34493722 Free PMC article.
Moreover, small-molecule targeting of REV-ERBalpha/BMAL1 by SR9009 ameliorates HFD-induced obesity in mice. Altogether, intestine clock functions as an accelerator in dietary fat absorption and targeting intestinal BMAL1 may be a promising approach for management of metabo …
Moreover, small-molecule targeting of REV-ERBalpha/BMAL1 by SR9009 ameliorates HFD-induced obesity in mice. Altogether, intestine clo …
106 results